A phase I, randomized, open-label, two-treatment, two-period, two-sequence, crossover study of ezetimibe/rosuvastatin in healthy Chinese participants under fasting conditions
Latest Information Update: 01 Jan 2025
At a glance
- Drugs Ezetimibe/rosuvastatin (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 17 Mar 2023 New trial record
- 10 Mar 2023 Results published in the Advances in Therapy